The National Institute for Health and Care Excellence (NICE) has published a final draft guidance which recommends use of icosapent ethyl in adults with CVD, statin-controlled LDL-c levels and elevated triglycerides.
Watch the videos in this series and learn about icosapent ethyl in relation to CV risk and its potential mechanisms of action!
In a subgroup analysis of REDUCE-IT, additional treatment with icosapent ethyl resulted in less ischemic events in statin-treated patients with prior MI.
Prof. Packard shares some thoughts on the potential mechanisms of benefit of icosapent ethyl as seen in the REDUCE-IT trial.
Watch a discussion by three experts on potential mechanisms, side effects, patient selection, parameters for monitoring and future studies with regard to icosapent ethyl.
What are key findings of two CV outcomes trials with icosapent ethyl? Prof. Jukema provides an overview and discusses remaining questions with regard to findings of REDUCE-IT. With poll.
There was no difference of icosapent ethyl efficacy among statin agents and statin categories (lipophilic vs. lipophobic statins) in an exploratory analysis of the REDUCE-IT trial.
AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.
AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.
What is the role of icosapent ethyl in lowering residual CV risk? Prof. Steg answers this question by presenting observations from trials with EPA-based therapies.
Is it relevant to discuss hypertriglyceridemia when LDL-c and inflammation are well-controlled? Prof. Stroes discusses the association of triglycerides and triglycerde-rich lipoproteins with CV risk.
Which formulation of omega-3 PUFAs should be used, and to whom and when should omega-3 PUFAs be prescribed? Prof. Lale Tokgözoğlu provides an overview of trials with omega-3 PUFAs and CV outcomes.